Brainstorm Cell Therapeutics Inc (STU:GHDN) Stock News, Headlines & Updates
Brainstorm Cell Therapeutics Inc Stock News from GuruFocus
- 1
Jun 14, 2024
BCLI: Initiation - Potential 10x Return on Successful Phase 3b. Promising Post Hoc and Biomarker Analysis Underpins Our NurOwn® Clinical Effectiveness Expectation
PRNewswire • 12:00pm
May 20, 2024
BrainStorm Cell Therapeutics to Present New Biomarker Data Suggesting ALS Patients May Benefit From Longer-Term Treatment with NurOwn
PRNewswire • 6:00am
May 14, 2024
BrainStorm Cell Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update
PRNewswire • 4:00pm
Apr 16, 2024
BrainStorm Cell Therapeutics Announces Management Changes as Company Plans Registrational Phase 3b Trial of NurOwn
PRNewswire • 6:00pm
Apr 11, 2024
BrainStorm Cell Therapeutics Regains Compliance with NASDAQ Minimum Market Value Rule
PRNewswire • 6:00am
Apr 10, 2024
BrainStorm Cell Therapeutics Announces Peer-reviewed Publication of Biomarker Data from NurOwn's® Phase 3 Clinical Trial in ALS
PRNewswire • 6:00am
Apr 09, 2024
BrainStorm Cell Therapeutics Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Phase 3b Trial in ALS
PRNewswire • 6:00am
Apr 08, 2024
BrainStorm Cell Therapeutics to Provide Update on NurOwn Program
PRNewswire • 6:00am
Apr 01, 2024
- 1
Show
Entries
Headlines
Total 0- 1
No recent news